INTRODUCTION {#neup12586-sec-0001}
============

Rosette‐forming glioneuronal tumor (RGNT) is a WHO grade I neoplasm usually occurring adjacent to or within the fourth ventricle, but is also described in other anatomic locations.[1](#neup12586-bib-0001){ref-type="ref"}, [2](#neup12586-bib-0002){ref-type="ref"}, [3](#neup12586-bib-0003){ref-type="ref"}, [4](#neup12586-bib-0004){ref-type="ref"} Histologic findings include two distinct morphologic components, one exhibiting neurocytic rosettes or perivascular pseudorosettes, and another component with fibrillary astrocytic cells similar to pilocytic astrocytoma.[5](#neup12586-bib-0005){ref-type="ref"} Characteristic molecular alterations include activating mutations in the phosphatidylinositol‐4,5‐bisphosphate 3‐kinase, catalytic subunit alpha gene (*PIK3CA*) structural rearrangements or activating mutations in the fibroblast growh factor receptor 1 gene (*FGFR1*), although these are not specific to RGNT.[6](#neup12586-bib-0006){ref-type="ref"} Some examples show morphologic and genetic overlap with dysembryoplastic neuroepithelial tumor (DNET), and this differential diagnosis can be challenging.[7](#neup12586-bib-0007){ref-type="ref"} RGNTs are rarely reported to undergo anaplastic change, with most examples occurring in association with radiation treatment.[2](#neup12586-bib-0002){ref-type="ref"}, [3](#neup12586-bib-0003){ref-type="ref"} In the central nervous system, alpha‐thalassemia with mental retardation syndrome, X‐linked gene (*ATRX*) mutations are typically associated with infiltrating astrocytomas with *IDH* gene mutations, and are also frequently seen in high‐grade gliomas with histone H3 p.K27M and H3.3 p.G34R or p.G34V mutations.[8](#neup12586-bib-0008){ref-type="ref"} More recently, *ATRX* mutations have been associated with high‐grade transformation in tumors histologically categorized as pilocytic astrocytomas.[9](#neup12586-bib-0009){ref-type="ref"} Here, we report a case of a recurrent epilepsy‐associated tumor histologically compatible with RGNT that showed anaplastic transformation and acquisition of an *ATRX* mutation in the absence of radiation or chemotherapy.

CLINICAL SUMMARY AND PATHOLOGIC FINDINGS {#neup12586-sec-0002}
========================================

A 1‐year‐old girl presented with developmental delay and seizures. Magnetic resonance imaging (MRI) identified a cystic temporal lesion (Fig. [1](#neup12586-fig-0001){ref-type="fig"}A). She was monitored by imaging until age 5, when new enhancement and growth of the lesion prompted a near total surgical resection. Histopathological findings were observed on the resected tissuesections stained with hematoxylin and eosin (HE). This specimen showed a moderately cellular neoplasm of monomorphic cells with round nuclei, perinuclear halos, a mucin‐rich background, and neurocytic rosettes (Fig. [1](#neup12586-fig-0001){ref-type="fig"}B). Other areas showed piloid cells with long thin processes and spindled nuclei (Fig. [1](#neup12586-fig-0001){ref-type="fig"}C). Synaptophysin immunoreactivity was intense and highlighted neuropil cores within the rosettes (Fig. [1](#neup12586-fig-0001){ref-type="fig"}D). Floating neurons and nodular architecture were not identified. The pathologic diagnosis at the initial resection was extraventricular neurocytoma with a focal DNET‐like pattern, WHO grade II.

![MRI findings of the brain (A, E), histopathological observations on the tumor sections stained with H&E (B, C, F, G) and immunohistochemical observations (D, H), FISH analysis of the tumor (I), and gene analyses of the tumor (J, K). The tumor is located at the left temporal lobe detected on T1‐weighted post‐contrast coronal views at 3 years old (A) and 15 years old (E), prior to the most recent GTR. New nodular enhancement appears at the resection cavity (E, arrow). Histological examinations on H&E‐stained sections show neurocytic cells, rosettes (B, inset), a mucoid background, and piloid features with elongated nuclei at 3 years old (B, C) and at the initial resection. The most recent GTR tissue shows low‐grade and high‐grade features (F, G). Synaptophysin immunoreactivity is detected in the initial resection tissue (D), while ATRX immunoreactivity is undetectable in the most recent GTR tissue (H). FISH analysis shows the results consistent with 1p/19q codeletion in the high‐grade areas (I). Sequencing traces of the most recent GTR tissue shows 5 duplication boundary within exon 10 and 3 duplication boundary within introns 18‐19 (J). Whole‐genome copy number profiling on the most recent GTR tissue shows whole‐arm 1p loss and only partial loss of chromosome arm 19q (asterisks) and focal copy number gain on chromosome 8 representing *FGFR1* kinase domain tandem duplication (red arrow). Scale bars: 100 μm (A--H).](NEUP-39-389-g001){#neup12586-fig-0001}

This patient subsequently underwent surgical gross total resection (GTR) of residual tumor at age 6, prompted by worsening epilepsy, and another GTR at age 11 for recurrent tumor. These resections were diagnosed as residual/recurrent extraventricular neurocytoma. Surveillance MRI at age 15 showed new nodular enhancement in the resection cavity (Fig. [1](#neup12586-fig-0001){ref-type="fig"}E), prompting a third GTR for recurrent disease. This most recent specimen showed regions resembling the original tumor (Fig. [1](#neup12586-fig-0001){ref-type="fig"}F). However, other areas showed high‐grade features with histology that closely resembled anaplastic oligodendroglioma (Fig. [1](#neup12586-fig-0001){ref-type="fig"}G). This included hypercellular sheets of cells with rounded nuclei and perinuclear cytoplasmic clearing, microvascular proliferation, palisading necrosis, and up to 13 mitotic figures per 10 high power fields. ATRX immunohistochemistry showed loss of nuclear staining in the high‐grade regions of tumor (Fig. [1](#neup12586-fig-0001){ref-type="fig"}H), and ATRX expression was retained in the low‐grade portion. Additional immunohistochemistry showed scattered neurofilament‐positive processes, scattered neuronal nuclear antigen‐positive cells, and CD34 staining of vascular endothelial cells only. The Ki‐67 labeling index was less than 2% in low‐grade areas, and up to 20% in high‐grade areas. Oligodendrocyte transcription factor 2 (OLIG2) was strongly positive in the tumor cells in both areas. This feature argued against a neurocytic neoplasm, and taken with the unusual clinical history and high‐grade histology, prompted additional molecular studies and reconsideration of the initial diagnosis.

Ancillary studies included fluorescence in situ hybridization (FISH) for 1p/19q, which showed codeletion limited to the high‐grade areas (Fig. [1](#neup12586-fig-0001){ref-type="fig"}I). Sanger sequencing of the genes for isocitrate dehydrogenase 1 (IDH1), IDH2, human histone 3.3 (H3F3A) was negative for mutations. No *BRAF* fusions were detected by FISH. To clarify the diagnosis and the relationship between the high‐grade specimen and the previous low‐grade neoplasm, next‐generation sequencing (NGS) studies were performed on tumor samples from the initial resection, the second recurrence, and the third recurrence which included the high‐grade histology. The UCSF 500 Cancer Gene Panel is a hybrid capture‐based NGS platform assessing mutation status of over 500 cancer‐associated genes, common gene fusions, and whole‐genome copy number profiling.[10](#neup12586-bib-0010){ref-type="ref"} This analysis showed an *FGFR1* kinase domain internal tandem duplication, with identical duplication breakpoints seen in all three specimens (Fig. [1](#neup12586-fig-0001){ref-type="fig"}J, 5′ duplication boundary within exon 10 and 3′ duplication boundary within introns 18‐19). This alteration is predicted to result in an in‐frame tandem duplication of *FGFR1* codons 438‐795, containing the intracellular tyrosine kinase domain.[11](#neup12586-bib-0011){ref-type="ref"} Sequencing also identified a p.R1427fs truncating *ATRX* mutation only in the third recurrence specimen, with a mutant allele frequency of 22%. The *ATRX* mutant allele was not detected in the previous specimens, with 408 reads at this locus from the initial resection specimen and 503 reads from the second recurrence specimen. Whole‐genome copy number profiling of the most recent specimen showed complete loss of chromosome arm 1p, but only partial loss of chromosome arm 19q, not the whole‐arm codeletion that is a required component for an integrated diagnosis of oligodendroglioma (Fig. [1](#neup12586-fig-0001){ref-type="fig"}K). A few distinct copy number alterations were seen across the three specimens, but the only shared abnormality other than *FGFR1* internal tandem duplication was monosomy 22q. Integrating the molecular and histologic findings across all of these specimens, a revised diagnosis of high‐grade neoplasm, most consistent with anaplastic RGNT was rendered. The patient has since completed a course of radiation therapy. She experienced a temporary increase in seizure activity, but is otherwise well, and surveillance imaging has not identified tumor recurrence at approximately 11 months after the most recent resection.

DISCUSSION {#neup12586-sec-0003}
==========

The conservation of the *FGFR1* kinase domain internal tandem duplication establishes this patient\'s case as a single tumor with multiple recurrences over approximately 14 years before undergoing spontaneous (i.e. without radiation therapy) anaplastic progression. After review of multiple specimens and external review, this tumor was determined to be most consistent with RGNT. Other entities were considered in the differential diagnosis, including DNET and extraventricular neurocytoma. The initial diagnosis of extraventricular neurocytoma with a focal DNET‐like pattern was excluded largely on the basis of strongly positive OLIG2 immunohistochemistry which was not available at our institution at the time of the initial diagnosis. DNET is a more difficult entity to definitively exclude, given the morphologic overlap with RGNT. However, the findings of distinctly synaptophysin‐positive neurocytic rosettes and areas with elongated cells with piloid processes are more typically seen in RGNT than DNET. The lack of conventional DNET cytologic and architectural features in any specimen such as floating neurons, nodularity, and a columnar organization to the glioneuronal element also argue against DNET and favor RGNT. While criteria for anaplastic RGNT are not defined, the presence of numerous mitotic figures, necrosis, and microvascular proliferation support the designation of anaplastic change in this particular case.

Targeted NGS has been shown to be of great benefit in the pediatric neuro‐oncology population, and in this case NGS results helped to arrive at a more precise diagnosis and provided an explanation for the unusual constellation of ATRX loss, wild‐type IDH1 and IDH2, and apparent 1p/19q‐codeletion by FISH. The 1p/19q‐codeletion in this setting introduced pediatric‐type oligodendroglioma into the differential diagnosis, although this codeletion is seen in only a minority of pediatric‐type oligodendrogliomas and they are predominantly low grade.[12](#neup12586-bib-0012){ref-type="ref"} Subsequent identification of only partial loss of 19q by whole‐genome copy number profiling illustrates that methodologies for detection of whole‐arm 1p and 19q loss should be considered as an adjunct to 1p/19q codeletion by FISH when apparent codeletion is unaccompanied by IDH mutation. The finding of ATRX immunohistochemistry loss limited to high‐grade regions of this tumor, accompanied by a confirmed *ATRX* mutation, suggests that RGNT may be another tumor in which *ATRX* gene mutation could be a potential driver of anaplastic progression. Finally, this case shows that the diagnosis of RGNT should not necessarily be restricted by anatomic location despite a preponderance of cases occurring near the fourth ventricle. A tumor with distinct neurocytic and piloid components and appropriate mutations such as *PIK3CA* or *FGFR1* should prompt consideration of the diagnosis regardless of location. While the behavior of RGNTs is thought to be relatively indolent, anaplastic progression can occur even in the absence of radiation therapy.
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